Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» Amgen
Amgen
Amgen builds Otezla’s psoriasis label as rival BMS looms large
Pharmaforum
Wed, 12/22/21 - 11:19 am
Amgen
Otezla
psoriasis
Bristol Myers Squibb
deucravacitinib
Abandoned by Amgen, Cytokinetics lands $50M upfront deal for Chinese rights to heart failure prospect
Fierce Biotech
Tue, 12/21/21 - 10:34 am
Cytokinetics
heart failure
Omecamtiv Mecarbil
Amgen
China
Ji Xing Pharmaceuticals
AstraZeneca and Amgen’s asthma biologic approved in the US
Biopharma Reporter
Mon, 12/20/21 - 11:08 am
AstraZeneca
Amgen
Tezspire
FDA
severe asthma
Bowing to pressure, J.P. Morgan says its health care conference will be virtual
Stat
Wed, 12/15/21 - 10:53 am
JPMHC 2022
virtual meetings
COVID-19
pandemic
Amgen
Moderna Therapeutics
Moderna, Amgen among biotech heavyweights pulling out of JPM conference over Covid concerns
Stat
Tue, 12/14/21 - 11:37 pm
JPMHC 2022
Amgen
Moderna
Sarepta Therapeutics
COVID-19
pandemic
Omicron COVID-19 variant
Amgen halts some drug discounts for safety net hospitals as SCOTUS takes on 340B case
Endpoints
Thu, 12/2/21 - 11:04 pm
Amgen
drug discounts
340B
Amgen's Otezla notches win in genital psoriasis, snagging possible edge against forthcoming BMS rival
Fierce Pharma
Thu, 12/2/21 - 12:25 pm
Amgen
Otezla
psoriasis
Bristol Myers Squibb
Amgen stalls Samsung's Enbrel biosim until 2029 in 2nd patent win of the year
Fierce Pharma
Wed, 12/1/21 - 10:14 am
Amgen
Enbrel
Samsung
biosimilars
patents
Amgen asks Supreme Court to take up its high-profile PCSK9 patent case against Sanofi and Regeneron
Fierce Pharma
Mon, 11/29/21 - 10:44 pm
Amgen
Sanofi
Regeneron
patents
Supreme Court
Repatha
Amgen's Otezla, Repatha and biosimilars put on notice, with challenging years ahead
Fierce Pharma
Mon, 11/22/21 - 10:13 pm
Amgen
biosimilars
Otezla
Repatha
Amgen, Biohaven, Lilly and Teva plowed plenty into marketing migraine meds. Is it working?
Fierce Pharma
Mon, 11/22/21 - 10:21 am
migraines
pharma marketing
JNJ
Topamax
Amgen
Biohaven
Eli Lilly
Teva Pharmaceutical
Merck’s Anti-Cholesterol Drug Threatens Esperion, Other PCSK9 Inhibitor Makers
BioSpace
Mon, 11/15/21 - 11:55 pm
Merck
PCSK9 inhibitors
Amgen
Repatha
Esperion
Sanofi
Regeneron
Praluent
Seeking an edge over Amgen, Mirati advances lower KRAS dose in Keytruda combo to improve tolerability
Fierce Biotech
Tue, 11/9/21 - 10:49 am
Mirati Therapeutics
Amgen
KRAS
clinical trials
Merck
Keytruda
Amgen breaks ground on New Albany, OH manufacturing plant of the future — report
Endpoints
Fri, 11/5/21 - 09:53 am
Amgen
drug manufacturing
Ohio
Why did FDA ask Amgen to add low-dose trial of Lumakras?
Korea Biomed
Wed, 11/3/21 - 10:47 am
FDA
Amgen
clinical trials
Lumakras
oncology
cancer
A three-decade monopoly: How Amgen built a patent thicket around its top-selling drug
BioPharma Dive
Mon, 11/1/21 - 11:56 am
Amgen
Enbrel
rheumatoid arthritis
patents
Buckle up AbbVie, Amgen: Biohaven's oral CGRP drug is gaining traction in migraine, doctors’ survey shows
Fierce Pharma
Fri, 10/22/21 - 12:42 pm
Biohaven
migraines
Nurtec ODT
Amgen
AbbVie
Amid Amgen's similar struggles, AstraZeneca slams the brakes on MCL-1 blood cancer drug
Fierce Biotech
Wed, 10/20/21 - 10:20 am
AstraZeneca
AZD5991
clinical trials
Amgen
blood cancer
Allied with Amgen and backed by $500M, Neumora brings data science to brain drugs
MedCity News
Thu, 10/7/21 - 12:19 pm
Neumora Therapeutics
R&D
Amgen
funding
data science
drug development
Bristol Myers Squibb's deucravacitinib flunks midphase IBD trial, raising questions about potential blockbuster
Fierce Biotech
Thu, 10/7/21 - 11:24 am
Bristol Myers Squibb
deucravacitinib
Amgen
Otzela
psoriasis
ulcerative colitis
Pages
« first
‹ previous
…
7
8
9
10
11
12
13
14
15
…
next ›
last »